Injecting a cancer medicine into tumors plus pembrolizumab
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 1/2 study tests a medicine injected directly into a tumor, alone or with pembrolizumab (an immune-therapy drug given through a vein). It is for people with advanced or metastatic solid cancers that have grown despite standard treatments, aiming to improve tumor control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older, with advanced or metastatic cancer that has progressed after standard treatment.
- Your cancer type must match one of the study groups (melanoma, head and neck cancer, sarcoma, cervical/“cSCC” skin cancer, or lung cancer without certain gene changes).
- You have at least one measurable tumor spot that the team can reach with an injection, and you must be well enough for treatment (ECOG 0–1).
- You should have recovered from prior cancer treatment side effects, and you must be able to wait at least 21 days after your last treatment (or 21 days after surgery/radiation).
- You must be willing to provide a fresh tumor biopsy (tissue sample) and sign consent before any study tests.
- You cannot have certain health issues that raise risk, like prior immunotherapy-related lung inflammation, uncontrolled infections, or active hepatitis B/C, HIV, or pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests the safety and early signs of benefit from CJRB-101 when combined with pembrolizumab (Keytruda) in people with advanced or metastatic lung, head and neck, or melanoma cancer. It may help some participants, but the main goal is to see how safe the combination is and whether it can control cancer.
This Phase 2 study tests whether adding a metabolic (diabetes-related) medicine to an immune therapy (pembrolizumab or nivolumab) can better control certain solid tumors. It may help people whose standard treatment would usually be pembrolizumab or nivolumab alone.
This Phase 1 trial tests a cancer vaccine (VAX014) injected directly into a tumor, given alone at first and then with an immune checkpoint medicine (nivolumab or pembrolizumab). It aims to see how well this approach is tolerated and may help shrink advanced solid tumors after other treatments stopped working.
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
This Phase 1/2 trial tests T3P, a new treatment given directly into reachable solid tumors, to see if it is safe and can help shrink tumors. It is for adults with advanced cancers when no curative treatment is available.
This early-phase trial studies OMTX705, given by itself or with an anti–PD-1 immune therapy, in people with advanced solid cancers that can’t be cured or that stopped responding to standard treatments. It aims to check safety and see whether the treatment can shrink tumors or control disease.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.